Autologous Matrix-Induced Chondrogenesis (AMIC)

Autologous Matrix-Induced Chondrogenesis (AMIC)

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market to Reach US$278.0 Million by 2030

The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$164.4 Million in the year 2023, is expected to reach US$278.0 Million by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Collagen, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period. Growth in the Hyaluronic Acid segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$52.8 Million While China is Forecast to Grow at 9.9% CAGR

The Autologous Matrix-Induced Chondrogenesis (AMIC) market in the U.S. is estimated at US$52.8 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$26.1 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market - Key Trends & Drivers Summarized

Autologous Matrix-Induced Chondrogenesis (AMIC) is an innovative surgical technique developed to treat articular cartilage defects in joints. This procedure combines microfracture surgery, which involves creating small holes in the subchondral bone to stimulate blood flow and cell migration, with the application of a biocompatible collagen membrane. The membrane serves as a scaffold to support the growth and differentiation of mesenchymal stem cells into chondrocytes, which are the cells responsible for producing cartilage. AMIC is primarily used in the knee, but it can also be applied to other joints such as the hip, ankle, and shoulder. This technique aims to repair cartilage damage, reduce pain, and improve joint function, offering a less invasive alternative to traditional cartilage repair methods like autologous chondrocyte implantation (ACI).

The procedure for AMIC begins with arthroscopic or mini-open surgery to access the cartilage defect. After debriding the damaged cartilage, microfractures are created in the underlying bone to release bone marrow elements rich in stem cells. A collagen membrane, typically derived from porcine or bovine sources, is then placed over the microfractured area and secured with fibrin glue or sutures. This membrane not only provides a physical barrier to protect the newly forming cartilage but also creates an optimal environment for the stem cells to proliferate and differentiate. Over time, these cells generate new cartilage tissue that integrates with the existing cartilage, promoting long-term joint health. The minimally invasive nature of AMIC allows for quicker recovery times and less postoperative discomfort compared to more invasive procedures.

The growth in the Autologous Matrix-Induced Chondrogenesis (AMIC) market is driven by several factors, reflecting advancements in medical technology, increasing prevalence of joint injuries, and the demand for effective cartilage repair solutions. One significant driver is the rising incidence of sports injuries and osteoarthritis, which has heightened the need for innovative treatments that can restore joint function and alleviate pain. Technological advancements in biomaterials and surgical techniques have also contributed to the adoption of AMIC, as these improvements enhance the effectiveness and reliability of the procedure. Additionally, the growing aging population, which is more susceptible to joint degeneration, has led to increased demand for cartilage repair therapies. The shift towards minimally invasive surgical techniques further supports the market growth, as patients seek procedures with shorter recovery times and lower risks. Regulatory approvals and favorable reimbursement policies in various regions are also encouraging the adoption of AMIC. These factors collectively drive the expansion and innovation in the AMIC market, ensuring its continued evolution and adoption in clinical practice.

Select Competitors (Total 28 Featured) -

• Anika Therapeutics, Inc.
• Arthro Kinetics Biotechnology GmbH
• B. Braun Melsungen
• CONMED Corporation
• Geistlich Pharma AG
• JRI Orthopaedics Ltd.
• Matricel GmbH
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.